Insulin glulisine

Summary

Insulin glulisine (Apidra) is a rapid‑acting human insulin analogue approved for improving glycaemic control in children, adolescents and adults with type 1 or type 2 diabetes. Delivered by subcutaneous injection or intravenously, it is designed to act faster and for a shorter period than regular human insulin, allowing flexible dosing around meals.

Mechanism of Action

Glulisine differs from regular insulin by a Lys substitution at B‑3 and a Glu substitution at B‑29, which reduce self‑association and eliminate the need for zinc. These changes keep the molecule primarily monomeric after injection, enabling rapid absorption. Once in circulation it binds the insulin receptor with similar affinity to human insulin, triggering the intracellular signalling cascade that promotes glucose uptake and suppresses hepatic glucose production.

What the Research Shows

Clinical reviews and pharmacokinetic studies report that insulin glulisine reaches peak plasma concentrations about twice those of regular insulin in roughly half the time, with an onset of action around 20 minutes and a duration of about 4 hours. Trials in type 1 and type 2 diabetes show comparable reductions in haemoglobin A1C to regular insulin (≈0.1 % lower) and similar glycaemic outcomes to other rapid‑acting analogues such as lispro and aspart. Post‑prandial glucose excursions are lower versus regular insulin and at least equivalent when compared with lispro. Safety data indicate hypoglycaemia rates and overall tolerability are similar to other insulins, with occasional localized or systemic allergic reactions. Evidence of superiority over other rapid‑acting analogues remains limited, and long‑term data beyond 26 weeks are scarce.

Reported Benefits

Glulisine’s rapid absorption provides a quicker onset (≈20 min) and higher early insulin exposure, which improves post‑prandial glucose control. Its shorter 4‑hour action window permits flexible dosing immediately before or up to 20 minutes after meals. Studies show it is as effective as regular insulin for A1C reduction and does not increase overall hypoglycaemia risk compared with other rapid‑acting insulins.

Limitations of the Evidence

Head‑to‑head trials with other rapid‑acting analogues, especially in type 2 diabetes, are limited, so definitive superiority has not been established. Long‑term safety and efficacy data beyond about six months are sparse. Dose‑proportionality plateaus above 0.15 U/kg, indicating a saturation effect. Rare allergic reactions have been reported, and cost considerations may affect formulary decisions.

Safety Considerations

Insulin glulisine is generally well tolerated; the incidence of hypoglycaemia is comparable to regular insulin and other rapid‑acting analogues. Reported adverse events include occasional local injection‑site reactions and rare systemic allergic responses. No unique safety signals have emerged in clinical trials, and its safety profile is described as favorable and similar to that of regular human insulin.

How It Is Administered

Glulisine can be administered subcutaneously or intravenously. Subcutaneous injections are typically given 15–20 minutes before a meal or up to 20 minutes after eating. The formulation is zinc‑free, allowing immediate availability of monomeric insulin for rapid absorption, and it can also be used in continuous subcutaneous insulin infusion pumps.

Routes of Administration

Goals & Uses

• Type 1 diabetes managementEndocrine/metabolicHigh
• Type 2 diabetes managementEndocrine / MetabolicHigh
• HbA1c reductionGlycemic ManagementHigh
• Glycemic controlDiabetesHigh
• Continuous subcutaneous insulin infusion (CSII)Delivery OptimizationModerate
• Postprandial glucose controlGlycemic ManagementHigh

Contraindications

• Severe insulin resistanceMetabolicModerate
• Hypersensitivity to insulin glulisine or excipientsImmunologicHigh
• HypoglycemiaMetabolicHigh

Adverse Effects

• EdemaFluid BalanceUncommonSwelling from fluid retention
• HypokalemiaElectrolyteUncommon
• HypoglycemiaMetabolicCommonAbnormally low blood glucose
• Allergic reactionsImmunologicalRare
• Injection site reactionsLocalUncommon
• Weight gainMetabolicCommonIncrease in body weight

Drug Interactions

• Beta-adrenergic blockersModerate
• Thiazolidinediones (e.g., pioglitazone)Moderate
• Concurrent use of other insulin productsHigh
• Beta-blockersModerate
• AlcoholModerate
• Sympathomimetics (e.g., epinephrine, salbutamol)Moderate
• CorticosteroidsModerate
• ACE inhibitorsLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Renal impairmentOrgan ImpairmentRelative
• Elderly patientsAgeRelative
• Pediatric patients under 4 yearsAgeRelative
• Pediatric patients (<2 years)AgeAbsolute

Regulatory Status

• European UnionApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusEMA approval for rapid-acting insulin therapy.
• United StatesApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusFDA approved 2004.
• United KingdomApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMHRA approval; same as EU.

Approved for subcutaneous administration in type 1 and type 2 diabetes; not interchangeable with other insulin products without dose adjustment.

Evidence & Sources

• Insulin glulisine: a review of its use in the management of diabetes mellitus
  Journal ArticleModerateGarnock-Jones KP, Plosker GL2009-01-01T00:00:00.000000Z
• Clinical pharmacokinetics and pharmacodynamics of insulin glulisine
  Journal ArticleModerateBecker RH, Frick AD2008-01-01T00:00:00.000000Z
• Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application
  Journal ArticleModerateHelms KL, Kelley KW2009-01-01T00:00:00.000000Z
• Insulin glulisine complementing basal insulins: a review of structure and activity
  Journal ArticleModerateBecker RH2007-01-01T00:00:00.000000Z
• Insulin glulisine
  Journal ArticleModerateCox SL2005-01-01T00:00:00.000000Z

Frequently Asked Questions